73162-95-5

Usage

Uses

Used in Veterinary Medicine:
Ivermectin B1a Aglycon is used as an anthelmintic agent for the treatment and control of various nematode infections in animals. Its ability to inhibit nematode larval development without causing paralytic activity allows for effective management of parasitic infections with reduced side effects.
Used in Pharmaceutical Research:
Ivermectin B1a Aglycon serves as a valuable compound in the research and development of new drugs targeting nematode infections. Its unique properties make it a promising candidate for the creation of novel therapeutic agents with improved efficacy and safety profiles.
Used in Agricultural Applications:
In the agricultural industry, Ivermectin B1a Aglycon can be utilized as a component in the development of new pesticides or animal health products. Its ability to inhibit nematode larval development can contribute to the control of parasitic infections in livestock, thereby improving overall animal health and productivity.
Used in Environmental Management:
Ivermectin B1a Aglycon may also find applications in environmental management, particularly in the control of nematode populations that can cause damage to crops or harm ecosystems. Its targeted approach to inhibiting nematode development without causing paralytic activity could provide a more sustainable and environmentally friendly solution for nematode control.

Upstream product

• 73162-95-5 22,23-dihydroavermectin B_1a aglycon 
• 71827-03-7 5-O-demethyl-22,23-dihydro-avermectin A₁a 

Downstream Products

• 73162-95-5 (8,9-Z)-22,23-dihydroavermectin B_1a aglycon 
• 73162-95-5 (10,11-Z)-22,23-dihydroavermectin B_1a aglycon 
• 73162-96-6 5-O-(tert-butyldimethylsilyl)-22,23-dihydroavermectin B₁ aglycon 
• 1258313-45-9 C₄₂H₅₇NO₉ 
• 1258313-44-8 C₄₁H₅₄ClNO₉ 
• 1258313-42-6 C₄₁H₅₄ClNO₉ 
• 1258313-40-4 C₄₁H₅₅NO₉ 

Relevant academic research and scientific papers

A milbemycin analogs and method for preparation thereof and use in pesticide

The invention discloses milbemycins analogues as well as a preparation method and application thereof in pesticides. The new milbemycins analogues have the following structural formula shown the specification, wherein R1 is 2-naphthyl, p-methylphenyl, met

USE OF AVERMECTIN DERIVATIVE FOR INCREASING BIOAVAILABILITY AND EFFICACY OF MACROCYLIC LACTONES

The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) wherein: (i) R1 is chosen from the group constituted of -CH(CH3)2, -CH(CH3)CH2CH3, or cyclohexyle, (ii) X represents -CH2-CH2-, or -CH=CH-, (iii) R2 is chosen from the group constituted of or -OH group, (iv) R3 is OH or NOH, (v) represents a single bond when R3 is OH, or a double bond when R3 is NOH, as an inhibitor of a membrane-bound protein which transports exogenous compounds out of target cells

The in vitro characterization of the iterative avermectin glycosyltransferase AveBI reveals reaction reversibility and sugar nucleotide flexibility

The glycosyltransferase AveBI, which is involved in the biosynthesis of the macrolide antihelmintic avermectin (AVM), was characterized in vitro. AveBI was confirmed to catalyze two separate iterative additions of l-oleandrose, and the reversibility of AveBI-catalyzed reaction was also demonstrated. Investigation of sugar nucleotide specificity revealed 10 unique sugar nucleotide substrates which, in combination with five distinct aglycones, led to the production of 50 differentially glycosylated AVM variants. Copyright